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Neutral endopeptidase (NEP, also known as neutral metalloendopeptidase, enkephalinase, CALLA, or E. C. 3.4.24.1 1) is a membranebound enzyme that cleaves a large variety ofpeptidic hormones including enkephalins, tachykinins (such as neurokinin A and substance P), and kinins (such as bradykinin and kallidin).' Although NEP is widely distributed in the body, the highest activity is normally found in the lung, particularly at the level of airway epithelium and smooth muscle.2 A major potential physiological role for NEP in human airways has recently been proposed. Its enzymatic activity may exert a "braking effect" on airway smooth muscle contraction by inactivating peptidic hormones released under inflammatory conditions including asthma. ' 3 Kinins in general, and bradykinin in particular, are naturally occurring vasoactive peptides formed de novo in body fluids and tissues during inflammatory processes which have also been implicated in the pathophysiology ofbronchial asthma and related allergic disorders. 4 Bradykinin is generated from circulating kininogens through proteolytic cleavage by a variety of enzymes, the most important of which are tissue and plasma kallikreins.5 Evidence that kinin generation may be increased under conditions which prevail in areas of allergic inflammation in the airways has recently been obtained from studies in asthmatic6-8 and rhinitic subjects.9'0 In addition, bradykinin is reported to possess many pharmacological properties pertinent to the pathogenesis of asthma, including vasodilatation and increased microvascular leakage," 12 bronchoconstriction, 13'14 activation of C fibre nociceptive sensory nerve endings,'5 16 and induction of non-specific bronchial hyperresponsiveness in animals. '7 The effector functions of bradykinin on the airways appear to be modulated by a variety of factors, including bradykinin hydrolysis by several peptidases. Little is known at present about the potential role of lung peptidases in modulating bradykinin-induced responses in vivo. There is increasing evidence that NEP may be the most important enzyme system involved in the degradation of bradykinin in the airways.'819 Although a number of animal studies have shown that the NEP inhibitor phosphoramidon20 enhances the bronchoconstrictor effect of bradykinin both in vitro2" and in vivo,'9 22 23 the role ofNEP in modulating airways responsiveness to bradykinin in man is not known.
The aim ofthe present study was therefore to investigate the effect of inhibiting endogenous NEP activity by inhaled phosphoramidon on bradykinin-induced bronchoconstriction and baseline airway calibre in asthmatic subjects. The repeatability of the bradykinin challenge procedure was determined according to the method described by Altman and Bland. 26 Values of PC20 bradykinin and histamine following treatment with phosphoramidon and placebo were logarithmically transformed to normalise their distribution and compared by the Student's t test for paired data. Concentration ratios for the effect of phosphoramidon against bronchoprovocation with each agonist were calculated by dividing the PC20 value obtained after administration of active drug by that obtained after placebo and compared using the Wilcoxon signed rank test.
Any relationship was examined by least squares linear regression analysis.
Results

EFFECT OF INHALED PHOSPHORAMIDON ON AIRWAY CALIBRE
There was no significant difference in baseline values of FEV, between any of the study days (table 2) . However, two minutes after administration of nebulised phosphoramidon FEV, values were significantly lower than their predrug values, decreasing 6x3% and 5x3% from 3x12 (0 23) to 2x93 (0x22)l (p<0-01; Cumulative concentration of histamine (mg/ml) The geometric mean (range) of PC20 values obtained were 1-72 (0 11-11 9) and 0-226 (0-014-4-467) mg/ml for histamine and bradykinin, respectively. In phase 2 inhaled phosphoramidon had a small but significant enhancing effect against the fall in FEV, produced by bradykinin (fig 1) , the geometric mean (range) PC20 values decreasing 2 1-fold from 0-281 (0-015-5-575) mg/ml after placebo to 0136 (0006-2-061)mg/ml after phosphoramidon (p<0 01). No correlation could be found between the degree of fall in FEVy values and the potentiation of airways response to bradykinin following exposure to phosphoramidon.
EFFECT OF INHALED PHOSPHORAMIDON ON CONCENTRATION-RESPONSE CURVE TO HISTAMINE
In phase 3 the same dose of inhaled phosphoramidon failed to alter the airways response to a subsequent inhalation with histamine ( fig  2) , despite being effective in inducing significant changes in baseline airway calibre (table 2) . The geometric mean (range) PC20 value of 1 65 (0 17-10 52) mg/ml after placebo was not significantly different from that of 1-58 (0-09-15-21) mg/ml obtained after phosphoramidon.
Discussion
In asthmatic subjects inhibition of NEP by inhaled phosphoramidon elicits a small but significant enhancement to the bronchospastic response provoked by bradykinin, without changing the response to histamine. These findings support the view that a functional NEP system is present and specifically limits the effects of the contractile oligopeptide bradykinin in asthmatic airways in vivo. In addition, it was interesting to note that exposure to phosphoramidon elicited a small but sig- seen after phosphoramidon may be the result of an irritant effect of the drug, but we cannot exclude other possibilities. Comparison between the subjects studied and those from previous studies showed no difference in their characteristics except for the use of inhaled corticosteroids. Phosphoramidon elicited a significant fall in FEVy only in the subjects taking inhaled steroids. The reason for this is not known, but we are currently exploring this finding in a series of controlled studies. As it has been shown that increased NEP activity is present in glucocorticoid-treated human epithelial cells,3' it is possible that inhaled steroids could increase NEP activity within the airways to such a level that the addition of a specific NEP inhibitor (phosphoramidon) might reveal a basal peptidergic tone. We have also shown the functional importance of endogenous NEP in modulating reactivity of the airways to exogenously administered bradykinin. That NEP inhibition has a specific effect on airways responsiveness to bradykinin is demonstrated by the lack of change in histamine reactivity after phosphoramidon. The present data are in line with the evidence provided by several authors on the potentiation of bradykinin-induced airways responses following NEP blockade in animal studies. 92 '21-3 Although the bradykinin challenge was repeatable to within one doubling dilution of agonist in eight out of nine subjects, it must be pointed out that the 2 1-fold potentiation of bradykinin responsiveness after phosphoramidon exposure should be interpreted with caution. However, the degree of potentiation shown in the present study with NEP inhibition is similar to that reported by us29 and others30 against the airway effect of neurokinin A in asthma. Thus, despite the fact that phosphoramidon is a potent inhibitor of NEP, its effect on bradykinin-induced airway changes may be negligible because of the hydrolysis of bradykinin by other lung peptidases including angiotensin converting enzyme (ACE, kininase 2) and carboxypeptidase N and M.45 This emphasises the importance of alternative enzymatic pathways in the modulation of kinin responses in man.
NEP degrades a variety ofpeptides including bradykinin by cleaving the Pro7-Phe8 bond, thereby releasing inactive peptidic fragments. '8 Because of its localisation on the plasma membrane, NEP may be involved in the local control of peptide hormone activity by inactivating or altering the receptor specificity of peptides at their site of action.' This view has been substantiated by a series of clinical investigations in normal28 and asthmatic subjects2930 in which potentiation of the bronchoconstriction induced by the neuropeptide neurokinin A was demonstrated following NEP blockade.
The mechanism ofbradykinin-induced bronchoconstriction in asthma is unknown but release of spasmogenic tachykinins is a possibility.4 The enhancing effect of phosphoramidon on bradykinin-induced bronchoconstriction might therefore have been the result of NEP directly contributing to brady-kinin metabolism or by metabolising endogenous tachykinins released by bradykinin. Indeed, we and others have shown that NEP inhibition significantly enhances the airways response to inhaled neurokinin A in healthy and asthmatic subjects. [28] [29] [30] In health, kinins usually exist in the circulating blood at very low concentrations as a result of the balance between their production and inactivation by plasma and tissue enzymes. In various respiratory diseases kinin levels may be raised and may dramatically impair airway function. Whilst inhalation of bradykinin aerosols was shown to have no detectable effect on airway calibre in normal subjects, when administered to patients with asthma it resulted in a concentration-related bronchoconstriction." Part of this discrepancy may be related to the loss of activity of the endogenous peptide degrading enzyme, NEP, which seems to occur in those conditions characterised by shedding of the airway epithelium -for example, acture viral infections, exposure to inhaled irritants, or bronchial asthma.3 Two recent studies have shown that mechanical removal of the respiratory epithelium increases the reactivity of the underlying smooth muscle of intact guinea pig trachea to the constrictor effects of several peptidic hormones including tachykinins and bradykinin.2132 As the enzyme NEP 24 11 is strongly expressed on airway epithelial cells2 and is very important in the degradation oftachykinins and kinins,1 removal of the airway epithelium may explain the enhanced constrictor effect of bradykinin. Shedding of the epithelium is commonly observed in the airways of asthmatic subjects3334 and this could contribute to the increased airways response to inhaled kinins in asthma.
In conclusion, this is the first demonstration of the potential physiological importance of NEP activity in regulating airways responsiveness to bradykinin in asthma in vivo. The study shows that exogenously administered bradykinin may be a suitable substrate for NEP in asthmatic airways, and that phosphoramidon given by inhalation is effective, not only in enhancing the bronchoconstrictor response of exogenously administered bradykinin, but also in reducing the airway calibre in most of our subjects, thus suggesting that a basal endogenous peptidergic tone is functionally active in asthmatic airways. We speculate that diseases or therapies that decrease endogenous pulmonary neutral endopeptidase may underline the importance of such enzymatic systems in the control of kinininduced changes in airway function. 
